HC Wainwright Reaffirms Buy Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Lexicon Pharmaceuticals (NASDAQ:LXRX)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They currently have a $10.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 498.80% from the stock’s current price.

Separately, StockNews.com upgraded Lexicon Pharmaceuticals to a “sell” rating in a research report on Tuesday, July 9th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $7.50.

Lexicon Pharmaceuticals Stock Down 1.2 %

Shares of LXRX opened at $1.67 on Wednesday. The company has a quick ratio of 11.49, a current ratio of 11.51 and a debt-to-equity ratio of 0.41. The stock has a market cap of $411.22 million, a price-to-earnings ratio of -2.01 and a beta of 1.33. Lexicon Pharmaceuticals has a 12 month low of $0.92 and a 12 month high of $3.73. The company has a 50-day moving average price of $1.83 and a two-hundred day moving average price of $1.90.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.01. The company had revenue of $1.65 million for the quarter, compared to the consensus estimate of $2.74 million. Lexicon Pharmaceuticals had a negative net margin of 5,509.34% and a negative return on equity of 105.38%. During the same quarter in the previous year, the company earned ($0.22) EPS. Equities analysts predict that Lexicon Pharmaceuticals will post -0.69 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of LXRX. Cantor Fitzgerald L. P. acquired a new position in Lexicon Pharmaceuticals during the 4th quarter valued at about $25,000. Principal Securities Inc. acquired a new stake in shares of Lexicon Pharmaceuticals during the 4th quarter worth approximately $33,000. CVI Holdings LLC bought a new stake in shares of Lexicon Pharmaceuticals during the second quarter worth approximately $34,000. Principal Financial Group Inc. lifted its holdings in Lexicon Pharmaceuticals by 116.1% in the second quarter. Principal Financial Group Inc. now owns 22,759 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 12,225 shares during the period. Finally, Victory Capital Management Inc. boosted its stake in Lexicon Pharmaceuticals by 22.0% in the fourth quarter. Victory Capital Management Inc. now owns 32,187 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 5,813 shares during the last quarter. Institutional investors and hedge funds own 74.70% of the company’s stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.